Scenesse (afamelanotide) is a protein pharmaceutical. Afamelanotide was first approved as Scenesse on 2014-12-22. It is used to treat erythropoietic protoporphyria in the USA. It has been approved in Europe to treat erythropoietic protoporphyria. It is known to target melanocyte-stimulating hormone receptor, melanocortin receptor 5, melanocortin receptor 4, and melanocortin receptor 3. Scenesse's patent is valid until 2029-03-11 (FDA).
|Drug Class||Peptides: melanocortin receptor antagonists|